Bullish indicating open at $55-$60, IPO prices at $37
LONDON - Ananda Pharma PLC (AQSE:ANA, OTCQB:ANANF) announced today that the first participant has been dosed in its Phase 1 pharmacokinetic study of MRX1, the company’s lead cannabidiol drug candidate, at a clinical site in Melbourne, Australia.
The open-label, multiple-dose study will assess the pharmacokinetic profile, safety, tolerability, and food effect of MRX1 in healthy adult volunteers. The trial has enrolled 20 participants divided into two treatment groups, with results anticipated in the first quarter of 2026.
According to the company’s press release statement, MRX1 is already advancing into Phase 2 clinical trials for endometriosis and chemotherapy-induced peripheral neuropathy. This Phase 1 study will run independently of those trials and is designed to characterize systemic exposure and support future dose optimization.
"This study is a strategic addition to the MRX1 program and sees us move from formulation development into full clinical execution," said Melissa Sturgess, Ananda’s CEO, in the announcement.
The study will last up to 52 days for participants in Group A and 37 days for those in Group B, including screening and follow-up periods. The company expects the last participant’s final dose to be completed within three months.
The trial follows the recent delivery of GMP-manufactured MRX1 to the Australian site and is being sponsored by Tiamat Australia Pty Ltd, Ananda’s wholly owned Australian subsidiary.
Ananda Pharma describes itself as a UK-based biopharmaceutical company developing regulatory approved cannabinoid medicines to treat complex, chronic conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.